Gao Peng, Tsai Chengche, Yang Yuchong, Xu Yingying, Zhang Changwang, Zhang Cong, Wang Longyi, Liu Hongpeng, Wang Zhenning
Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China.
Department of Breast Surgery, First Hospital of China Medical University, Shenyang, China.
Minerva Med. 2017 Feb;108(1):74-83. doi: 10.23736/S0026-4806.16.04628-0. Epub 2016 Oct 4.
The treatment effects of intraoperative radiotherapy (IORT) for gastric and esophageal cancer remain uncertain. We therefore performed meta-analyses to investigate whether IORT was associated with more favorable oncologic outcomes when compared to non-IORT for patients who have gastric or esophageal cancer.
PubMed, Embase, and the references of relevant studies were systematically searched up to March 2016. Outcomes were analyzed with fixed-effect or random-effect models, and the meta-analysis was completed with odds ratio (OR), hazards ratio (HR), and 95% confidence intervals (CI) as effect values.
Eleven studies were included, nine for gastric cancer and two for esophageal cancer. The studies included 1581 patients, 570 in the IORT group and 1011 in the control group. There was no significant difference in overall survival (OS) between the IORT group and control group (HR=0.91, 95% CI: 0.73-1.13; P=0.38). Two subgroups based on cancer type also had the similar results (gastric group: HR=0.98, 95% CI: 0.78-1.24, P=0.87; esophagus group: HR=0.63, 95% CI: 0.37-1.05, P=0.08). Besides, IORT showed favorable effects for patients with cancer in stage II and stage III and had the advantage of loco-regional control. Regarding the complications, the occurrence rate had no significant difference between the IORT group and control group (OR=1.15; 95% CI: 0.77-1.72; P=0.50).
According to our meta-analysis, IORT did not extend the OS in gastric cancer and esophageal cancer patients, but had a favorable effect for specific stage patients to show loco-regional control, and did not increase the risk of complications.
术中放疗(IORT)对胃癌和食管癌的治疗效果仍不确定。因此,我们进行了荟萃分析,以研究与未接受IORT的胃癌或食管癌患者相比,IORT是否能带来更有利的肿瘤学结局。
截至2016年3月,系统检索了PubMed、Embase及相关研究的参考文献。采用固定效应或随机效应模型分析结局,并以比值比(OR)、风险比(HR)和95%置信区间(CI)作为效应值完成荟萃分析。
纳入11项研究,其中9项针对胃癌,2项针对食管癌。这些研究共纳入1581例患者,IORT组570例,对照组1011例。IORT组与对照组的总生存期(OS)无显著差异(HR=0.91,95%CI:0.73-1.13;P=0.38)。基于癌症类型的两个亚组也有相似结果(胃癌组:HR=0.98,95%CI:0.78-1.24,P=0.87;食管癌组:HR=0.63,95%CI:0.37-1.05,P=0.08)。此外,IORT对II期和III期癌症患者显示出良好效果,并具有局部区域控制优势。关于并发症,IORT组与对照组的发生率无显著差异(OR=1.15;95%CI:0.77-1.72;P=0.50)。
根据我们的荟萃分析,IORT并未延长胃癌和食管癌患者的OS,但对特定分期患者显示出局部区域控制的良好效果,且未增加并发症风险。